Fractyl Health, Inc. - Common Stock – Cashflow (NASDAQ:GUTS)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -65.52 M-90.33 M -87.73 M Mittelzufluss aus Investitionstätigkeit -1.76 M-557 K — Zahlungsströme aus der Finanzierungstätigkeit 101.23 M104.96 M 108.89 M Freier Cashflow -65.52 M-90.89 M -87.83 M

Fractyl Health, Inc. - Common Stock

Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1.

GUTS

Financials

Fractyl Health, Inc. - Common Stock

Nachrichten

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

Diabetes-Gentherapie: Fractyl Health erhält Zulassung für klinische Studie in den Niederlanden

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

Earnings Call: Fractyl Health senkt Kosten, doch Aktie gibt nach Quartalszahlen nach

Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Fractyl Health: Low Market Expectations Create Trading Opportunity With 2026 Catalysts

Morgan Stanley stuft Fractyl Health nach enttäuschenden Studienergebnissen zu Revita herab

Morgan Stanley downgrades Fractyl Health stock rating to Equalweight on Revita trial results

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11%

Why Is Fractyl Health Stock Tumbling Today? - Fractyl Health (NASDAQ:GUTS)

Fractyl Health-Aktie bricht nach Studiendaten zur Gewichtserhaltung ein